cabozantinib,atezolizumab
roche
['contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
contact-03 presented by . no benefit to addition of atezo second line post-progression on io. major implications for 2l rcc treatment #asco23 
GU Oncologist at @UHhospitals